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Recombinant adeno-associated virus (rAAV) are effec-
tive gene delivery vehicles that can mediate long-lasting 
transgene expression. However, tight regulation and 
 tissue-specific transgene expression is required for certain 
therapeutic applications. For regulatable expression from 
the liver we designed a hepatospecific bidirectional and 
autoregulatory tetracycline (Tet)-On system  (TetbidirAlb) 
flanked by AAV inverted terminal repeats (ITRs). We char-
acterized the inducible hepatospecific system in com-
parison with an inducible ubiquitous expression system 
(TetbidirCMV) using luciferase (luc). Although the ubiqui-
tous system led to luc expression throughout the mouse, 
luc expression derived from the hepatospecific system 
was restricted to the liver. Interestingly, the induction 
rate of the TetbidirAlb was significantly higher than that 
of TetbidirCMV, whereas leakage of TetbidirAlb was signif-
icantly lower. To evaluate the therapeutic potential of 
this vector, an AAV-Tetbidir-Alb-expressing interleukin-12 
(IL-12) was tested in a murine model for hepatic col-
orectal metastasis. The vector induced dose-dependent 
levels of IL-12 and interferon-γ (IFN-γ), showing no sig-
nificant toxicity. AAV-Tetbidir-Alb-IL-12 was highly efficient 
in preventing establishment of metastasis in the liver and 
induced an efficient T-cell memory response to tumor 
cells. Thus, we have demonstrated persistent, and induc-
ible in vivo expression of a gene from a liver-specific Tet-
On inducible construct delivered via an AAV vector and 
proved to be an efficient tool for treating liver cancer.
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IntroductIon
Adeno-associated virus (AAV) is a naturally replication-defective 
single-stranded DNA parvovirus. The lack of pathogenicity of the 
virus, its persistence, long-term expression and relative lack of 
immune response have contributed to the increase in popularity 
of AAV vectors.1,2 The clinical efficacy and safety as well as the 
application range of AAV vectors will be broadened by developing 
systems capable of finely modulating the expression of therapeutic 
genes.3,4 In particular, treatment of malignancies by gene trans-
fer of immunostimulatory proteins requires precise control over 
expression in order to avoid or reduce associated side effects. A 
regulatable system that can turn “on” and “off ” therapeutic gene 
expression will not only be crucial for maintaining appropriate 
levels of a gene product within the therapeutic range, prevent-
ing any toxicity, but also allow the turning “off ” of therapeutic 
gene expression to avoid harmful side effects. The development of 
drug-dependent transcription regulatory systems is thus of great 
importance.3,4
Tetracycline (Tet)-regulatable systems are based on the 
Escherichia coli Tn10 Tet-resistance operon, which consists of the 
Tet repressor protein (TetR) and the Tet operator DNA sequence 
(TetO DNA). In the absence of Tet or its derivate doxycycline 
(Dox) the TetR protein binds to the TetO DNA sequence and 
blocks gene expression, whereas in the presence of the drug, TetR 
changes its conformation and detaches from the DNA.3,4 This 
system has been modified to transform the Dox repressor sys-
tem into a Dox inducible system (Tet-On system). In the Tet-On 
system, the reverse Tet transactivator (rtTA) fusion protein com-
posed of the Dox-binding TetR mutant (now called rTetR) and the 
C-terminal activator domain from the herpes simplex virus VP16 
protein was engineered to control gene expression with Dox. In 
the presence of Dox, the rtTA transactivator activates the activ-
ity of minimal promoters fused downstream of an array of seven 
TetO sequences.3,4
Tet-responsive regulatory systems are normally cloned in two 
different expression cassettes, one containing the regulatory pro-
tein (tTA) and the second one containing the Tet regulatory ele-
ment fused to a minimal promoter, regulating the expression of 
the reporter or therapeutic transgene. These types of constructs are 
difficult to fit into a recombinant AAV (rAAV) vector due to the 
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limited cloning capacity (~4.9 kb).5 For this reason, we developed 
a single Tet-inducible autoregulated expression system pTetbidirON, 
whose small size allowed regulated expression in AAV vectors.6,7 
In this system, the transcription of both the rtTA and the trans-
gene is initiated from a ubiquitous bidirectional, Tet-responsive 
promoter. Furthermore, a bidirectional polyadenylation sequence 
flanking the inducible system was included to insulate the expres-
sion cassette from the weak promoter activity of the inverted ter-
minal repeats (ITRs). Using this system, an 80-fold induction in 
vivo in the rat brain has been obtained.6,7 Based on this principle, 
we have developed a hepatospecific Tet-On expression system. 
For this purpose, we replaced the minimal CMV promoter used in 
the original construct with the notably weak liver-specific murine 
albumin promoter.8,9 To characterize both inducible systems 
after systemic administration, expression cassettes-containing 
luciferase (luc) gene were packaged into AAV serotype 8 capsids 
(AAV8). AAV8, a serotype discovered in rhesus monkeys, is able 
to mediate robust transgene expression in various mouse tissues, 
being particularly efficient in liver transduction. Luc allows for 
monitoring of long-term in vivo expression and biodistribution 
analysis, where expression levels can be easily quantified using a 
cooled charge-coupled device camera or equivalent in vivo imag-
ing systems.10
Interleukin-12 (IL-12) is a potent cytokine endowed with 
strong antitumor properties. IL-12 can serve as a link between the 
innate and adaptative immune responses because it can activate 
the proliferation of T lymphocytes and natural killer cells, the 
secretion of other inflammatory mediators such as interferon-γ 
(IFN-γ) and also activate the cytotoxic activity of these effec-
tor cells.11 In addition, IL-12 exerts an important antiangiogenic 
effect. These functions make this cytokine an attractive candidate 
to stimulate the immune response against cancer cells. The capac-
ity of IL-12 to increase the number and activity of tumor-specific 
lymphocytes has been verified in humans, and specific antitumor 
effects have been observed.12 However, clinical responses tend to 
be poor, and intensification of the treatment is difficult due to the 
toxicity associated with systemic exposure to IL-12.12,13 The use of 
gene transfer strategies to obtain expression of the cytokine in spe-
cific locations is an attractive alternative.14–16 However, the clinical 
experience indicates that refinement of these vectors is needed. 
Intratumor administration of a replication-deficient adenoviral 
vector encoding the IL-12 gene was well tolerated in patients with 
hepatic metastases. Biological effect was demonstrated, but anti-
tumor responses were very modest.16 The poor performance of 
the vector in terms of intensity and duration of expression was 
recognized as a key limitation in this approach. To circumvent 
these problems recombinant viral vectors capable of mediating 
long-term and sustained expression of IL-12 might be used. High-
capacity adenovirus or AAV vectors represent ideal candidates to 
obtain sustained but controlled levels of the cytokine in serum.17
In this study, we demonstrate the ability of the hepatospecific 
Tet-regulatable system to establish long-term transgene regula-
tion restricted to the liver following intravenous (i.v.) injection of 
AAV8 vector. Furthermore, the use of this vector encoding IL-12 
cytokine plus Dox for 7 days prevents the development of MC38-
derived liver metastasis and prolonged survival in 90% of mice 
with no side effects.
results
luc expression after i.v. administration  
of AAV-ptetbidir-cMV-luc and AAV-ptetbidir-Alb-luc
First, we tested luc expression biodistribution in vivo, after i.v. 
administration of an AAV8 vector harboring an autoregulated 
Tet-inducible system in which the expression of the transactivator 
and the gene of interest is under the control of TetO7 fused CMV 
minimal (CMVm) promoters (AAV8-Tetbidir-CMVm-luc) or the 
TetO7 fused albumin promoters8 (AAV8-Tetbidir-Alb-luc). A third 
vector was constructed in which the expression of the transactiva-
tor is under the control of the TetO7 fused albumin promoter and 
the expression of the gene of interest is under the control of TetO7 
fused CMVm (AAV8-Tetbidir-Alb-CMVm-luc). All the constructs 
have been schematically represented in Figure 1a. Two groups 
of four BALB/c female mice received a dose of 5 × 1012 vector 
genomes (vg)/kg of either vector. Two weeks after vector injection 
luc expression was analyzed before (basal) and 24 hours after the 
intraperitoneal (i.p.) administration of Dox at a dose of 50 mg/
kg. The optimal dose of Dox for transgene expression was experi-
mentally determined (Supplementary Figure S1a). As shown 
in Figure 1b, luc expression in mice that received AAV8-Tetbidir-
Alb-luc was confined to the liver, whereas a broader distribution 
of expression was detected in the animals AAV8-Tetbidir-CMVm-
luc or AAV8-Tetbidir-Alb-CMVm-luc to quantify luc expression 
a region of interest covering the whole animal was drawn (as 
described in Supplementary Figure S1b). Quantification of the 
signal before induction revealed that leakage from the CMVm or 
the CMV-Alb promoter-inducible system was higher than from 
the albumin promoter-inducible system (Figure 1c). However, 
after Dox administration, luc expression was significantly higher 
in animals injected with AAV8-Tetbidir-Alb-luc or AAV8-Tetbidir-
Alb-CMVm-luc than in the animal injected with AAV8-Tetbidir-
CMVm-luc. The induction rate for AAV8-Tetbidir-pCMVm-luc, 
AAV8-Tetbidir-Alb-CMVm-luc, and AAV8-Tetbidir-Alb-luc was 3-, 
80-, and 250-fold, respectively (Figure 1c). The viral genome cop-
ies in the liver were analyzed using a quantitative-PCR specific for 
the transactivator-expressing gene and no significant differences 
were observed (Supplementary Figure S2).
Mice injected with AAV8-Tetbidir-Alb-luc were reinduced 15, 
30, and 60 days after vector injection and luc expression reached 
similar levels after each induction (Figure 1d). To analyze whether 
sustained transgene expression can be obtained with the liver-
specific vector, AAV8-Tetbidir-Alb-luc, male and female BALB/c 
mice were injected i.v. with a dose of 5 × 1012 vg/kg. Two weeks 
after injection, luc expression was induced by a single i.p. injection 
of Dox and expression induction was maintained by continuous 
administration of Dox in drinking water over the course of a week 
(2 mg/ml Dox + 5% sucrose). As shown in Figure 1e, luc expres-
sion can be maintained by administration of Dox for at least 1 
week. Furthermore, the extinction of luc expression after removal 
of Tet was very rapid, as shown in Figure 1f, where 48 hours after 
removing Dox, expression of luc returned to basal levels.
Ex vivo biodistribution analysis
To corroborate the liver specificity of the vector, BALB/c and 
C57BL/6 mice of both genders (n = 7) were injected i.v. with 
5 × 1012 vg/kg of AAV8-Tetbidir-pAlb-luc, AAV8-Tetbidir-CMV-luc. 
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Twenty-one days later, luc expression was induced by i.p. injection 
of 50 mg/kg Dox in five animals per group, whereas two animals 
were left untreated. Twenty-four hours later, mice were analyzed 
for luc expression using the living image IVIS system and then 
sacrificed and organs harvested. Luc expression was analyzed 
from organ extracts using a luminometer. Results with C57BL/6 
mice are shown in Figure 2, whereas similar results were also 
obtained with BALB/c mice (Supplementary Figure S3). Ex vivo 
luc expression analysis corroborates what was observed in vivo. 
Luc expression was restricted to the liver in all mice that received 
AAV8-Tetbidir-Alb-luc whereas luc expression was detected in sev-
eral organs in addition to the liver in mice injected with AAV8-
Tetbidir-CMV-luc. The biodistribution of luc expression of vector 
AAV8-Tetbidir-CMV-luc was similar to previous data obtained by 
our group using a rAAV8 encoding luc under the control of the 
constitutive and ubiquitous promoter:10 in female mice luc expres-
sion can be detected mainly in the liver followed by the heart, 
ovary, and uterus (Figure 2a) and at lower levels in the stomach, 
muscle, lung, intestine, and kidney. In males, luc expression was 
detected in the liver and in the heart, followed by intestine and 
stomach at lower levels, muscle (Figure 2b). Biodistribution of 
luc expression after AAV8-Tetbidir-Alb-CMVm-luc was similar to 
the one found for AAV8-Tetbidir-CMVm-luc vector in the absence 
of induction. However, after Dox administration luc was induced 
only in the liver in the animals that received AAV8-Tetbidir-Alb-
CMVm-luc while was induced in all the transduced organs in ani-
mals injected with AAV8-Tetbidir-CMVm-luc (data not shown).
In vitro and in vivo characterization  
of AAV8-tetbidir-Alb-Il-12
To construct AAV8-Tetbidir-Alb-IL-12, the luc reporter gene was 
replaced by the gene encoding single chain of IL-12.18 The induc-
ibility and hepatospecificity of the system were first tested in vitro. 
Human HepG2, PLC/PRF/5, and HuH-7 cell lines of hepatic 
origin, as well as HEK293 and HeLa cells of nonhepatic origin 
were transfected with the pro-AAV plasmid containing the AAV-
Tetbidir-Alb-IL-12 genome. Four hours after transfection, Dox was 
added to the culture medium at a concentration of 1 μg/ml and 48 
hours later supernatants were harvested from induced and nonin-
duced cells. As shown in Figure 3a, IL-12 was only detected in the 
supernatant of the induced hepatic cells and not in the superna-
tants from HEK293 or HeLa cells.
For in vivo analysis, C57BL/6 female mice received three 
different doses of pAAV8-Tetbidir-Alb-IL-12: 1.5 × 10
12, 5 × 1011, 
1.5 × 1011 vg/kg (n = 5 per group). Twenty-one days after virus 
injection, IL-12 expression was induced by i.p administration of 
Dox, and then maintained by the administration of Dox in drink-
ing water (at a concentration of 2 mg/ml). IL-12 levels in serum 
were measured before and 1, 4, 7, and 10 days after i.p. administra-
tion of Dox. We had previously determined in the MC38 syngeneic 
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Figure 1 In vivo characterization of AAV-ptetbidir-cMV-luc and AAV-ptetbidir-Alb-luc. (a) Schematic diagram of tetracycline-inducible adeno- associated 
viral (AAV) vectors used in this study. Alb, albumin promoter; CMVm, minimal early cytomegalovirus promoter; ITR, inverted terminal repeat; luc, 
luciferase gene; polyA, SV40 fragment containing the early and late polyadenylation signals; rtTAM2, mutated reverse tetracycline transactivator; TetO7, 
sequence-containing seven tetracycline operator sites. (b) BALB/c mice injected with 5 × 1012 vg/kg of AAV8-Tetbidir-CMVm-luc, AAV-Tetbidir-Alb-luc or 
AAV8-Tetbidir-Alb-CMVm-luc were analyzed with the charge-coupled device (CCD) camera before and 24 hours after administration of doxycycline (Dox). 
Shown are optical CCD images for luciferase expression of representative animal from each group, 1 day postinduction. (c) Luciferase expression was 
quantified and represented as photons/second. The data are shown as mean ± SD. The differences on luciferase expression was statistically evaluated by 
Student’s t-test (*P < 0.05, ***P < 0.001). (d) Mice injected with AAV-Tetbidir-Alb-luciferase were reinduced 15, 30, and 60 days after vector injection and 
luciferase expression was measured. (e) AAV8-Tetbidir-Alb-luc, male and female BALB/c mice were injected intravenous (i.v.) with a dose of 5 × 10
12 vg/kg. 
Two weeks after injection, luciferase expression was induced by a single intraperitoneal (i.p.) injection of Dox and expression induction was maintained 
by continuous administration of Dox in drinking water over the course of a week. Each dot represents the average of the decimal logarithm of biolumi-
nescence for each group of animals at a time point. (f) The extinction time of luciferase expression was determined after removal of Dox.
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tumor model that serum concentrations of IL-12 <20 ng/ml have 
no antitumor effect, and levels >1,000 ng/ml are associated with 
toxicity.17 The analysis of IL-12 expression before and after Dox 
administration showed that IL-12 cannot be detected by enzyme-
linked immunosorbent assay in the absence of Dox. Twenty-four 
hours after administration of Dox, serum IL-12 levels reached 
maximal levels, which correlate with the dose of rAAV8 vector 
injected. After that, IL-12 levels leveled off reaching undetectable 
levels 7 days after administration of Dox (Figure 3b). In contrast, 
the same induction regime, given to mice injected with an equiva-
lent vector expressing luc resulted in the expression of sustained 
levels of the transgene (Figure 1e). These results indicate that, as 
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Figure 3 In vitro and in vivo characterization of AAV8-tetbidir-Alb-Il-12 construction. (a) Analysis of interleukin-12 (IL-12) expression by enzyme-
linked immunosorbent assay (ELISA) in the supernatant of hepatic (HepG2, PLC/PRF/5, and HuH-7) and nonhepatic cells (HEK293, HeLa) after pAAV8-
Tetbidir-Alb-IL-12 plasmid transfection and administration of doxycycline (Dox). (b, c) For in vivo characterization C57BL/6 female mice received three 
different doses of AAV8-Tetbidir-Alb-IL-12: 1.5 × 10
12, 5 × 1011, 1.5 × 1011 vg/kg (n = 5). Twenty-one days after injection of the rAAV8 vector IL-12 
expression was induced by the administration of 50 mg/kg of Dox and then maintained via the administration of Dox in drinking water at a concen-
tration of 2 mg/ml. (b) IL-12 and (c) interferon (IFN)-γ levels in serum were measured by enzyme-linked immunosorbent assay (ELISA) before and 1, 
4, 7, and 10 hours after administration of Dox. AAV8, adeno-associated virus serotype 8; Alb, albumin promoter; rAAV, recombinant AAV.
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Figure 2 Ex vivo biodistribution analysis of luciferase expression after AAV8-tetbidir-Alb-luc or AAV8-tetbidir-cMV-luc injection. (a) Male and 
(b) female C57BL/6 mice were intravenous (i.v.) injected with 5 × 1012 vg/kg of AAV8-Tetbidir-CMVm-luc or AAV-Tetbidir-Alb-luc. Twenty days after virus 
injection luciferase expression was induced by intraperitoneal (i.p.) administration of doxycycline (Dox) at a dose of 50 mg/kg and 24 hours later all 
the animals were sacrificed and organs dissected. The levels of luciferase activity (RLUs) were determined in organ homogenates and were normalized 
to protein content (RLU/mg). The data are shown as mean ± SEM. AAV, adeno-associated virus; CMV, cytomegalovirus; luc, luciferase gene.
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previously reported, the function of drug-inducible expression 
systems is influenced by the immunostimulatory properties of 
IL-12, acting at the transcriptional level.19
Since IFN-γ is the main mediator of IL-12 antitumoral activ-
ity, IFN-γ levels were measured before administration of Dox and 
1, 4, 7, and 10 days after induction. Analysis of IFN-γ expression 
showed that the maximum levels were reached 7 days after admin-
istration of Dox and decreasing thereafter (Figure 3c). The levels 
of IFN-γ expression were proportional to the dose of virus with 
average levels of 2,000, 1,000, and 250 pg/ml for doses 1.5 × 1012, 
5 × 1011, 1.5 × 1011 vg/kg, respectively. Regarding toxicity, very 
slight or no elevation in serum transaminases were detected dur-
ing the induction period. However, higher viral dose, 5 × 1012 vg/
kg, induces transaminase elevation and the dead of 30% the ani-
mals (Supplementary Figure S4).
Antitumoral effect of AAV8-tetbidir-Alb-Il-12 vector
C57BL76 female mice were injected with two different doses 
of AAV8-Tetbidir-Alb-IL-12 vector 1.5 × 10
12, 5 × 1011, and 
1.5 × 1011 vg/kg (n = 10). Other mice were administered saline 
solution instead of vector and Dox (negative control group). One 
month after vector administration, hepatic tumors were estab-
lished by direct implantation of 5 × 105 MC38Luc120,21 murine 
colorectal cancer cells in the left liver lobe following medial 
laparotomy in isofluorane-anaesthetized animals. Cell engraft-
ment was verified by bioluminescence 2–3 days later. Ten days 
after the inoculation of the tumor cells, IL-12 expression induction 
was performed as described previously, that is, by administration 
of 50 mg/kg i.p., followed by administration of Dox via drinking 
water for 6 days. A schematic representation of the experiments is 
provided in Figure 4a. IL-12 and IFN-γ expression levels before 
and after administration of Dox were in accordance with the result 
as described in Figure 3b,c (data not shown).
Eighty and a hundred days after cell implantation all the ani-
mals from the control and from the group receiving the lowest 
dose of the AAV8-Tetbidir-Alb-IL-12, respectively, had died as a 
consequence of tumor progression. In contrast, none of the ani-
mals receiving 5 × 1011 vg/kg died and only two mice from the 
group receiving the highest dose died as a consequence of tumor 
progression at day 105. The rest of the mice were alive and free of 
tumor 100 days after cell implantation (Figure 4b). A represen-
tative image from AAV-Tetbidir-Alb-IL-12 (5 × 10
11 vg/kg) treated 
and control mice was shown (Figure 4c).
After showing that AAV8-Tetbidir-Alb-IL-12 vector prevents 
tumor development, we analyzed the antitumoral efficacy of this 
vector in a therapeutic antitumoral assay. A schematic representa-
tion of the experiments is provided in Figure 4d. Hepatic tumors 
were established by direct implantation of 5 × 105 MC38Luc1 cells, 
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Figure 4 Intravenous administration of AAV8-tetbidir-Alb-Il-12 results in antitumoral activity. (a) Schematic representation of the antitu-
moral prophylactic study. (b) C57BL/6 female mice were injected with three different doses of AAV8-Tetbidir-Alb-IL-12 vector 1.5 × 10
12, 5 × 1011, 
1.5 × 1011 vg/kg (n = 10). A group of mice were inoculated with saline solution instead of vector and doxycycline (Dox) (control group) (n = 10). 
One month after vector administration, hepatic tumors were established by direct implantation of 5 × 105 MC38Luc1 cells in the left liver lobe 
following medial laparotomy of isofluorane-anaesthetized mice. Cell engraftment was verified by bioluminescence 2–3 days later. Ten days after 
the inoculation of the tumor cell, interleukin (IL)-12 expression induction was performed as described previously, that is, by intraperitoneal (i.p.) 
administration of 50 mg/kg, followed by administration of Dox via drinking waster for 6 days. (c) Representative images from a mouse belonging 
to the group treated with 5 × 1011 vg/kg AAV8-Tetbidir-Alb-IL-12 and a mouse treated with saline. (d) Schematic representation of the antitumoral 
therapeutic study. (e) Hepatic tumors were established by direct implantation of 5 × 105 MC38Luc1 cells in the left liver lobe following medial 
laparotomy of isofluorane-anaesthetized mice. Cell engraftment was verified by bioluminescence 2–3 days later. Seven days after tumor injection 
mice were treated with vg/kg of AAV8-Tetbidir-Alb-IL-12 vector or saline (n = 10). Fifteen days after the inoculation of the tumor cell, IL-12 expression 
induction was performed as described previously, that is, by i.p. administration of 50 mg/kg, followed by administration of Dox via drinking waster 
for 6 days. Kaplan–Meier survival analysis of mice with established MC38 tumors after treatment is assessed (***P < 0.01). AAV8, adeno-associated 
virus serotype 8; Alb, albumin promoter; s.c. subcutaneous.
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7 days after cell injection 10 animals were treated with 5 × 1011 vg/
kg AAV-Tetbidir-Alb-IL-12 or saline. Eight days after vector injec-
tion IL-12 expression was induced by Dox administration, as 
previously described. Eighty-five days after cell implantation all 
the animals from the control group had died as a consequence of 
tumor progression whereas only one animal of the treated group 
died 105 days after cell injection (Figure 4e).
Protection against rechallenge
Protection from tumor relapse or from the appearance of new liver 
metastases is crucial to improve the prognosis of patients with col-
orectal cancer. Therefore, we studied the immunological protec-
tion against a tumor rechallenge. Animals that remained free from 
their hepatic tumors for more 120 days after cell implantation 
(n = 9) received a new inoculation of 1 × 106 MC38Luc1 cells in 
a (subcutaneous) distant location. Monitoring the tumor growth 
revealed that, on average, pretreated mice presented a delay in 
tumor progression compared with naive animals (Figure 5a,b). 
Furthermore, four out of nine mice were completely protected 
against tumor development while the five naive animals that were 
injected at the same time developed large tumors (Figure 5a,b). 
To appreciate this difference, in Figure 5c, we show the individual 
size of subcutaneous tumors at the end of the observation period. 
Photographs of representative liver tumors in control and AAV 
treated mice are shown in mice Figure 5c.
Twenty-three days after tumor rechallenge, the percent-
age of MC38-specific CD8 T cells were determined in blood. 
Higher expansion of CD8+ T lymphocytes specific for MC38 
cells in peripheral blood were observed in the group previously 
treated with AAV8-Tetbidir-Alb-IL-12 (Figure 5d) compared with 
untreated mice.
We also evaluated the presence of CD8+ T lymphocytes specific 
for MC38 cells in the tumors at the time of sacrifice (45 days after 
rechallenge). We detected a significantly higher number of MC38-
specific CD8 T cells in the tumor of mice previously treated being 
50% of the CD8+ cells tetramer positive (Figure 5e), suggesting a 
major role of CD8 T-cell population in IL-12-mediated antitumor 
immune response, as previously described.
dIscussIon
The use of cytokines with strong antitumor effects for the treat-
ment of malignancies will probably require repeated administra-
tions to achieve effective levels, whereas for many patients the 
therapeutic effect is hampered by the systemic toxicity of these 
cytokines. Gene transfer strategies offer the possibility to express 
the therapeutic gene in the target organ reducing systemic toxic-
ity. Furthermore, the use of a regulatable expression system will 
allow for controlling transgene expression levels with the ability to 
turn off expression once the therapeutic effect has been obtained 
or if severe toxicity is observed.3,4 rAAV vectors are promising 
gene delivery vehicles with distinct advantages in terms of being 
able to mediate long-term gene expression with minimal pathoge-
nicity.1,2 Therefore, in this study, we pursued two main aims: (i) the 
construction of a Tet-On system to allow tight regulation of gene 
expression in the liver mediated by an AAV8 vector and (ii) appli-
cation of such a vector encoding IL-12 to treat liver malignancies.
One of the limitations of the rAAV vectors system is a lim-
ited cloning capacity of ~4.9 kb,5 although for AAV5, there are 
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Figure 5 AAV8-tetbidir-Alb-Il-12 vector treatment induces a memory immune response and protects mice against rechallenge. Mice that 
remained free from hepatic tumors for >1 month after being treated with AAV8-Tetbidir-Alb-IL-12 vector (n = 9) (treated group) received a subsequent 
inoculation of 1 × 106 MC38Luc1 cells in a distant (subcutaneous) location as well as a group of five naive animals (control group). (a–b) Monitoring 
of tumor growth revealed that, on average, pretreated mice presented a delay in tumor progression compared with naive animals. (c) Individual size 
of subcutaneous tumors at the end of the observation period. (d) Representative images of subcutaneous tumor developed in a mouse from treated 
and control group. (e) Twenty-three days after tumor rechallenge the percentage of MC38-specific CD8+ T cells were determined in blood by tetramer 
staining in AAV8-Tetbidir-pAlb-IL-12-treated group and in the naive group The percentage of CD8
+tetramer+ cells from total peripheral blood lympho-
cytes is represented. (f) At the end of the experiment, tumors were removed and lymphocytes were isolated to determine the proportion of MC38-
specific CD8 T cells from the total number of infiltrating CD8 cells. AAV8, adeno-associated virus serotype 8; Alb, albumin promoter; IL, interleukin.
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reports of an increased capacity.22 For this reason regulated gene 
expression systems for AAV vectors usually consists of two AAV 
vectors: one that expresses a regulatory molecule which interacts 
with a small molecule inducer, and another, in which expression 
of the transgene of interest is controlled by a regulatory DNA 
region that reacts with the regulatory protein/inducer–molecule 
complex. The two AAV system requires coinfection by both vec-
tors for a given cell to provide regulated expression.23 However, in 
this study, we have used a system previously described, in which 
both expression cassettes fits into one AAV. In this system, all 
necessary elements of a two-expression cassette system are con-
tained within 3.5 kb of DNA. In this Tet-inducible AAV vector 
(AAV-TetbidirOn) the transcription of both the rtTA (rtTAM2) 
and the transgene is initiated from a bidirectional Tet-responsive 
promoter and terminated at bidirectional SV40 polyadenylation 
sites flanking both ITRs.8 In the present study, we have developed 
a liver-specific Tet-inducible AAV vector by replacing CMVm 
promoters by albumin promoters.9 We have also constructed a 
hybrid vector in which the expression of the transactivator is 
controlled by the albumin promoter and the expression of the 
transgene by the CMVm promoter.
When we compared in vivo the constitutive and liver-specific 
systems delivered by AAV vectors, the background expression in 
the absence of Dox was significantly higher when the expression 
system contains the minimal CMV promoter than with the liver-
specific promoter in both male and female mice from BALB/c 
and C57BL/6 strains. The lower basal expression levels is most 
likely related with the lower transcriptional activity of the albu-
min promoter in comparison with the minimal CMV promoter, 
as has been previously reported.8,9 Thus, the introduction of 
the Alb promoter reduces basal expression from transduced 
tissues. In general, the background expression levels from an 
inducible system directly correlates with its’ inducibility, where 
higher levels of expression in the absence of inducer is associated 
with higher rates of induction. Unexpectedly, we showed that 
the liver-specific inducible system led to very low basal expres-
sion, whereas the inducibility is significantly higher than the 
CMVm-based system (250-fold induction versus 3-fold induc-
tion). These results were corroborated by the use of the expres-
sion system containing both promoters, that showed mixed 
characteristics. The leakage of the system was higher and it has 
a wider biodistribution, however after induction the expression 
levels were similar to the ones obtained with the liver-specific 
expression cassette. For some therapeutic transgenes, it might be 
more important to obtain the highest possible level of induced 
expression, where higher levels of background expression may 
be tolerable. For other transgenes, especially those coding for 
toxic gene products, it might be critical to have the lowest pos-
sible background, with a high level of induced expression. The 
analysis of IL-12 expression showed that in the absence of Dox 
IL-12 is undetectable in serum whereas very high levels can be 
detected after Dox administration.
The molecular bases for the higher inducibility of the liver-
specific inducible system are unknown. Both vectors contain 
exactly the same TetO7 sequence and we only found minor dif-
ferences between both vectors at the 5′ and 3′ which are 9 and 17 
nucleotides longer, respectively, in the liver-specific system than 
in the ubiquitous system. More experiments should be performed 
to elucidate the striking differences in the inducibility of both 
systems.
The in vivo characterization of the liver-specific inducible 
expression system demonstrated that expression of the luc trans-
gene could be reinduced for several months by simply injecting 
Dox, or adding Dox to the animals’ drinking water. Furthermore, 
transgene expression was rapidly turned off upon withdrawal of 
the antibiotic. Forty-eight hours after the removal of Dox, luc 
expression returned to basal levels.
When the luc gene was replaced with the therapeutic gene for 
IL-12, we saw no basal expression and a clear viral dose-dependent 
induction of cytokine expression with Dox. However, in contrast 
with the pattern of luc expression, continuous administration of 
the inducer resulted in a marked decrease of IL-12 expression, 
disappearing 7 days after the first day of Dox injection. This effect 
may be related to promoter silencing or loss of DNA by degra-
dation. Previous studies performed by Reboredo et al.,19 have 
shown that biologically active IL-12 can transiently inhibit the 
function of drug-inducible systems plasmid vectors by reducing 
promoter activity, probably through IFN-γ and protein deacety-
lation-dependent mechanisms. Most likely, this will be also the 
situation after rAAV vector injection because IL-12 expression in 
IFN-γ receptor knockout mice resulted in sustained expression of 
IL-12 after administration of Dox (data not shown).
To test the antitumoral potential of AAV8-Tetbidir-pAlb-IL-12, 
the murine colorectal cancer cell line MC38 has been used as a 
model for poorly immunogenic tumors. Using this murine model 
of metastatic colon cancer to the liver in both prophylactic and 
therapeutic assays, we found a complete eradication of tumors in 
most of the animals treated with AAV8-Tetbidir-Alb-IL-12 and Dox 
for 7 days, whereas all animals that received saline, showed pro-
gressive tumor growth and death before 3 months. The antitumor 
treatment occurred without toxicity as indicated by the absence 
of a detectable rise in serum transaminase levels and long-term 
survival of all AAV8-Tetbidir-Alb-IL-12-treated mice. Furthermore, 
rechallenge experiments indicate that the mice have developed an 
MC38-specific memory T-cell response.24 The antitumoral effi-
cacy of rAAV8 vector is better that the one showed by first genera-
tion adenoviral vector expressing the same cytokine and similar to 
the efficacy showed by Semliki forest virus expressing IL-12 under 
similar experimental settings.25–27
In conclusion, we have demonstrated long-term, persistent, 
and inducible in vivo expression of a gene from a liver-specific 
Tet-On inducible construct delivered via an AAV vector. Our 
system provides a powerful molecular tool to switch transgene 
expression on and off in vivo in the liver, allowing its delivery only 
for a desired period of time, thus improving the efficacy of thera-
peutic gene transfer and limiting their toxicity. Furthermore, this 
vector enabled tight regulation of the cytokine IL-12 and proved 
to be an efficient tool for treating liver cancer. These vectors com-
bine a good antitumoral efficacy with a good safety profile.
MAterIAls And Methods
Viral construct. The pAC1-M2 plasmid comprising AAV2 ITRs flanking 
the bidirectional Tet-responsive cassette expressing both rtTAM2 and 
enhanced green fluorescent protein has been described previously.6 To 
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obtain the plasmid: AAV-Tetbidir-CMVm-luc, the luc cDNA was amplified 
using primers flanked by SalI and NotI sites, using pAlb-luc8 as template 
and was subsequently subcloned into pCR2.1 to obtain pCR2.1-luc. The 
SalI-NotI fragment obtained from pCR2.1-luc was inserted into pAC1-
M2 previously digested with SalI and NotI, replacing the GFP gene with 
luc. To obtain the AAV-Tetbidir-Alb-luc, first a sequence-containing seven 
Tet operator sites fused to the albumin promoter was amplified by PCR 
using as template the plasmid pTonL2(T)-mIL-128 and primers contain-
ing AfeI and EcoRI sites at 5′ends and subcloned into pCR2.1 to obtain 
pCR2.1-TetO7-Alb. In a second step, the albumin promoter was amplified 
using primers containing AfeI site and subcloned into pCR2.1. To obtain 
pCR2.1-Alb, the albumin promoter was excised with AfeI and cloned into 
pCR2.1-TetO7-Alb to obtain the plasmid pCR2.1-Alb-Teto7-Alb. After 
sequencing, the fragment Alb-TetO7-Alb was excised with EcoRI and 
SalI and cloned into AAV-Tetbidir-CMVm-luc previously digested with 
the same enzymes and replacing CMV-TetO7-CMV by Alb-TetO7-Alb, 
obtaining the plasmid AAV-Tetbidir-Alb-luc. To obtain the plasmid, AAV-
Tetbidir-Alb-IL-12, luc gene was excised from AAV-Tetbidir-Alb-luc by SalI-
NotI digestion, the IL-12 single chain gene was excised using the same 
enzymes from pCR2.1-scIL-12,18 and ligated to AAV-Tetbidir-Alb.
AAV8 production, purification, and titration. rAAV8 vectors with wild-
type AAV2 ITRs were produced by calcium phosphate-mediated co-trans-
fection in HEK293 cells.28 For each production a mixture of plasmids, 20 μg 
of pro-AAV plasmid and 55 μg pDP8.ape (PlasmidFactory, KG, Bielefeld, 
Germany), was transfected into 293 T cells 15-cm plate using linear poly-
ethylenimine 25 kDa (Polysciences, Warrington, PA) as described.29 The 
cells were harvested 48 hours after transfection and virus was released 
from the cells by three rounds of freeze–thawing. Crude lysate from all 
batches was then treated with Benzonase (50 U/ml crude lysate) for 1 hour 
at 37 °C and then kept at −80 °C until purification. Purification of crude 
lysate was performed by iodixanol gradients according to the method of 
Zolotukhin et al.30 The purified batches were concentrated and diafiltrated 
by cross-flow filtration (Spectrum Laboratories, Rancho Dominguez, CA) 
with a molecular mass cutoff of 400 kDa. The batches were then concen-
trated further by passage through Centricon tubes (YM-100; Millipore, 
Bedford, MA) to a final concentration of 1 × 1012 vg/ml, as determined by 
quantitative-PCR. After concentration, the viral batches were filtered (pore 
size, 0.22 mm) and stored at −80 °C. Viral titers in terms of genome copies/
ml were determined by quantitative-PCR, performed three times in tripli-
cate at three different dilutions.
Bioluminescence imaging. Mice were immobilized with i.p. anesthesia 
(a mixture of xylacine and ketamine). The substrate d-luciferin (150 μg/
kg dissolved in phosphate-buffered saline; Promega, Madison, WI) was 
injected i.p. Ten minutes later, animals were placed in the dark chamber 
for light acquisition in an IVIS charge-coupled device camera system 
(Xenogen, Alameda, CA) and analyzed with the Living Image 2.20 soft-
ware package (Xenogen). A region of interest covering the whole animal 
was defined, and quantification of light emission was performed in pho-
tons/second. Time exposure ranged from 1 second to 5 minutes depend-
ing on light intensity.10
Luc measurement. Organ sections were frozen in liquid nitrogen until pro-
cessed. Tissue was homogenized in Luciferase Lysis Reagent (Promega). 
Samples were centrifuged for 15 seconds at 12,000g. Supernatant was col-
lected and measured in a tube luminometer. Total proteins were quantified 
using the Bradford assay using bovine serum albumin as a standard.10
Mice, tumor models, and treatment. Male and female BALB/c and 
C57BL/6 mice (6–8 weeks old) were obtained from Harlan Laboratories 
(Barcelona, Spain) and maintained according to the guidelines of our 
institution. For AAV biodistribution studies, mice received the virus 
via tail vein in a volume of 200 μl. Dox was administered i.p. in a 200 
μl of saline solution. For all procedures, mice were anesthetized with 
ketamine–xylazine. Hepatic tumors were established by direct implan-
tation of 5 × 105 MC38Luc1 cells in the left liver lobe of C57BL/6 
mice following medial laparotomy in isofluorane-anaesthetized ani-
mals. Cell engraftment was verified by bioluminescence 2–3 days later. 
Characterization of this tumor model has been previously described.20,21 
For subcutaneous tumor formation (rechallenge experiments) a total of 
106 cells were injected in the right hind flank. In both cases, cells were 
resuspended in a total volume of 50 µl saline solution. Tumor size was 
monitored at indicated time points by measuring two perpendicular 
tumor diameters using a precision calliper. Tumor volume was calcu-
lated using the following formula: V = length × width2 × 0.5. Survival was 
checked daily and mice were euthanized if general status was deteriorated 
or subcutaneous tumors exceeded 20 mm in diameter. All in vivo studies 
were performed in accordance with the local animal commission.
Cell lines. HEK293, 293T, HeLa, HepG2, PLC/PRF/5, and HuH-7 cell 
lines were purchased from the ATCC (Manassas, VA) and were cultured 
in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal 
bovine serum and 100 U/ml penicillin/streptomycin. One microgram of 
plasmid was transfected, using polyethylenimine with 1 μg of AAV-Tetbidir-
Alb-IL-12.29 Briefly, 25-kDa branched polyethylenimine was used at an 
nitrogen to phosphate (N/P) ratio of 10 and using NaCl 150 mmol/l as 
the vehicle; 5 × 105 cells were plated in six-well plates and 24 hours later 
were transfected. After 24 hours, supernatant were collected and stored 
at −80 °C.
Determination of IL-12 and IFN-γ. Concentration of murine IL-12 and 
IFN-γ were determined by OptE1A mouse IL-12 (p70) and mouse IFN-γ 
enzyme-linked immunosorbent assay kits (BD Bioscience-Pharmingen, 
San Diego, CA).
Determination of serum levels of aspartate aminotransferase and ala-
nine aminotransferase. The blood level of aspartate amino transferase and 
alanine aminotransferase were measured using commercial kits (Sigma 
Chemicals, St Louis, MO) in a Hitachi Automatic Analyzer (Boehringer 
Mannheim, Indianapolis, IN).
Antibodies and flow cytometry. Single-cell suspensions were pretreated 
with FcR-Block (anti-CD16/32 clone 2.4G2; BD Bioscience-Pharmigen). 
Afterward, cells were stained with the following antibodies: CD8a fluo-
rescein (fluorescein isothiocyanate)-conjugated (53–6.7; eBioscience, 
San Diego, CA). To identify specific tumor CD8 T lymphocytes, cells 
were stained with the iTAg major histocompatibility complex class I 
tetramer loaded with the KSPWFTTL synthetic peptide and conjugated 
with PE (Beckmann Coulter, Madrid, Spain). Cells were analyzed with a 
FACSCalibur (BD) and FlowJo software.
Statistical analysis. Statistical analysis was performed with a two-tailed 
Student’s t-test for unpaired samples or a Mann–Whitney nonparametric 
test (GraphPad Prism software). Survival curves were compared by logrank 
test (GraphPad Prism software).
suPPleMentArY MAterIAl
Figure S1. In vivo determination of the optimal dose of Dox to 
induce Luc expression and region of interest (ROI) drawn to analyze 
Luc expression.
Figure S2. Viral genome copies were quantified by Q-PCR in the liver 
of mice injected with AAV8-Tetbidir-CMVm-luc, AAV8-Tetbidir-Alb-luc, 
and AAV8-Tetbidir-Alb-CMVm-luc.
Figure S3. Ex vivo biodistribution analysis of luciferase expression 
 after AAV8-Tetbidir-pAlb-luc or AAV8-Tetbidir-CMV-luc injection in female 
and male BALB/c mice.
Figure S4. Analysis of serum AST levels in animals treated with 
5 × 1012, 1.5 × 1012, and 1.5 × 1011 vg/kg AAV8-Tetbidir-Alb-IL-12 vector 
before and 1 and 7 days after Dox administration.
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